Abstract:Protein-protein interactions between SH2 domains and segments of proteins that include a post-translationally phosphorylated tyrosine residue (pY) underpin numerous signal transduction cascades that allow cells to respond to their environment. Dysregulation of the writing, erasing, and reading of these posttranslational modifications is a hallmark of human disease, notably cancer. Elucidating the precise role of the SH2 domain-containing adaptor proteins Crk and CrkL in tumor cell migration and invasion is challenging because there are no specific and potent antagonists available. Crk and CrkL SH2s interact with a region of the docking protein p130Cas containing 15 potential pY-containing tetrapeptide motifs. This chapter summarizes recent efforts toward peptide antagonists for this Crk/CrkL-p130Cas interaction. We describe our protocol for recombinant expression and purification of Crk and CrkL SH2s for functional assays and our procedure to determine the consensus binding motif from the p130Cas sequence. To develop a more potent antagonist, we employ methods often associated with structure-based drug design. Computational docking using Rosetta FlexPepDock, which accounts for peptides having a greater number of conformational degrees of freedom than small organic molecules that typically constitute libraries, provides quantitative docking metrics to prioritize candidate peptides for experimental testing. A battery of biophysical assays, including fluorescence polarization, differential scanning fluorimetry and saturation transfer difference nuclear magnetic resonance spectroscopy, were employed to assess the candidates. In parallel, GST pulldown competition assays characterized protein-protein binding in vitro. Taken together, our methodology yields peptide antagonists of the Crk/CrkL-p130Cas axis that will be used to validate targets, assess druggability, foster in vitro assay development, and potentially serve as lead compounds for therapeutic intervention.

C2 Region-derived Peptides Inhibit Translocation and Function of β Protein Kinase C in Vivo

β-Catenin Controls the Electrophysiologic Properties of Skeletal Muscle Cells by Regulating the α2 Isoform of Na + /K + -ATPase.

Cytosolic Peptides Encoding Ca V 1 C-termini Downregulate the Calcium Channel Activity-Neuritogenesis Coupling

Effects of prenyl pyrophosphates on the binding of PKCgamma with RACK1

Study on Selectivity of Inhibitor BD2 for PKA over PKC beta II

Identification and Structure Characterization of a Cdk Inhibitory Peptide Derived from Neuronal-specific Cdk5 Activator

Break CDK2/Cyclin E1 interface allosterically with small peptides.

Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis

Progress of the function and mechanism of protein kinase A RⅡβ

Break CDK2/Cyclin E1 Interface Allosterically with Small Peptides

The Roles of the RIIβ Linker and N-terminal Cyclic Nucleotide-binding Domain in Determining the Unique Structures of the Type IIβ Protein Kinase A

[Inhibitory Effect and Its Kinetic Analysis of Baicalein on Recombinant Human Protein Kinase CK2 Holoenzyme].

RACK1 facilitates breast cancer progression by competitively inhibiting the binding of β-catenin to PSMD2 and enhancing the stability of β-catenin

A novel bivalent interaction mode underlies a non-catalytic mechanism for Pin1-mediated protein kinase C regulation

RACK1 associates with CLEC-2 and promotes its ubiquitin-proteasome degradation.

Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes.

Computational Modeling and Characterization of Peptides Derived from Nanobody Complementary-Determining Region 2 (CDR2) Targeting Active-State Conformation of the β2-Adrenergic Receptor (β2AR)

Opto-chemogenetic inhibition of L-type CaV1 channels in neurons through a membrane-assisted molecular linkage

Phospho-substrate profiling of Epac-dependent protein kinase C activity

New Protein Kinase C Activator Regulates Amyloid Precursor Protein Processing In Vitro By Increasing Alpha-Secretase Activity

Identification of peptides interfering with the LRRK2/PP1 interaction